Abbott Laboratories Common Stoc (NYSE:ABT):
Abbott Receives FDA Approval for the FreeStyle Libre Proâ¢ System, a Revolutionary Diabetes Sensing Technology for Healthcare Professionals to Use with Their Patients.
In the market the company is trading up from yesterday’s close of $42.33.
Abbott Laboratories Common Stoc also announced a dividend which was paid on Monday August 15th, 2016. The dividend was $0.260 per share for the quarter or $1.04 on an annualized basis. The dividend yield was $2.47. The ex-dividend date was Wednesday the 13th of July 2016.
Company chares are trading at $42.35 a tad below $42.84, the stock’s 50 day moving average and which is just a bit higher than the 200 day moving average of $41.26. The 50 day moving average moved down $-0.44 and the 200 day average went up $1.14 or +2.75%.
The company’s P/E ratio is 27.99 and market cap is 62.33B.
A few brokerage analysts have weighed in on Abbott Laboratories Common Stoc recently. On September 13 Jefferies held the company rating at “Buy” but moved down the price target to $48.00 from $49.00. July 14 investment analysts at Jefferies kept the company rating at “Buy” and raised the price expectation from $45.00 to $49.00.
On June 21 the company was set at “Buy” according to a Edward Jones report which was a boost from the previous “” rating. On June 14 Jefferies kept the stock rating at “Buy” but lowered the price target to $45.00 from $47.00.
On April 28 the stock rating was downgraded from “” to “Buy” with a current price target of $47.00 in an announcement from Piper Jaffray. On March 15 Jefferies maintained a stock rating of “Buy” and moved up the price target from $45.00 to $47.00.